Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1310Carcinoma, Renal Cell 661Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 334Neoplasms 301Carcinoma, Transitional Cell 264Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 228Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 98Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma, Clear Cell × Genitourinary × Clear all
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Xencor, Inc.

Phase 2 Active not recruiting
170 enrolled
GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡